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ABSTRACT 
Introduction Objective of the study was to explore the impact of health insurance and 
socio-demographic factors on survival for breast cancer patients in Kentucky. Breast 
cancer is the most prevalent cancer among women in the US. Breast cancer survival is 
affected by various factors including health insurance, residence, age, race, geographical 
distance, income.  
Methods The data were obtained from Kentucky Cancer Registry and included 47,128 
women diagnosed with primary breast cancer between 2000 to 2014. The relationship of 
health insurance and other socio-demographic factors was analyzed using Cox regression. 
Results The overall five-year survival proportion was 0.97, 0.76 and 0.71 respectively for 
privately insured, Medicaid and Medicare patients. Medicaid and Medicare patients had 
1.89 (95% CI, 1.71-2.10), 1.96 (95% CI, 1.75-2.18) times higher hazard of dying 
respectively compared to privately insured patients. Patients who had no family history of 
breast cancer had a 15% (HR=1.15, p-value<0.001) higher hazard of dying compared to 
those having family history of breast cancer. Tobacco use and marital status also had 
significant effect on patient’s survival. Other tumor related and biological factors were also 
included in the regression model. Sub group analysis by SEER summary stage also showed 
that Medicaid and Medicare patients significantly at disadvantage compared to privately 
insured patients for both in-situ and regional stage groups. Medicaid patients had 
1.41(HR=1.41, p-value=0.0020) times higher hazard of death compared to privately 
insured patients whereas Medicare patients and the privately insured patients had no 
difference in hazard of death for distant stage group. Sub group analysis by age group also 
showed Medicare and Medicaid patients are disadvantaged compared to privately insured 
patients for all age groups.  
Conclusion This study found that Medicaid and Medicare patients had higher hazard of 
dying compared to privately insured patients. This helps to inform public health 
professionals and policy makers for advocacy and design policies that bring equal health 
outcomes regardless of insurance types. 
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BACKGROUND	
 
Breast cancer is one of the most commonly occurring cancers among women 
worldwide 1 and in the United States (US).2 About one in eight women develop invasive 
breast cancer over the course of their lifetime2 and an estimated 3,327,552 women were 
living with breast cancer in 20143; and 236,968 women were diagnosed with breast cancer 
while 41,211 women died from breast cancer in the US in the same year.4 It is estimated 
that 266,120 women will be diagnosed with breast cancer in 2018. However, the relatively 
higher survival probability (i.e. 89.7%) of five years or more for breast cancer patients is 
positive outcome.5 Nevertheless, there is noticeable disparity in survival probability of 
patients depending on the type of health insurance and other socio-demographic factors. 
Health insurance is a mechanism through which a person’s health care expenses are 
financed. There are different types of health insurance coverage in the US. Health insurance 
policy can be broadly categorized into public and private health insurance plans, which can 
further be identified into different sub-types. Public health insurance is provided with 
Medicaid, Medicare and military coverage. Private health insurance is primarily provided 
with employer-based insurance, followed by direct-purchase private plan.6  
Health insurance has been increasingly recognized as a modifiable policy determinant 
that affects the health of individuals. Studies have found that uninsured and Medicaid 
insured breast cancer patients have poorer outcomes than cancer patients with private 
insurance.7-11 Health insurance not only affects the survival of a patient after diagnosis, it 
also affects the survival and quality of life through differential access to screening and thus 
stage at diagnosis. A higher proportion of uninsured and Medicaid patients are diagnosed 
with stage III and stage IV compared to privately insured patients.12 Several factors 
including race, ethnicity, sociodemographic status, age, and reproductive factors affect the 
incidence and the mortality pattern of breast cancer in a population.13,14 Substantial and 
consistent disparities in quality of cancer care exist according to types of health insurance. 
15 Race, stage at the time of diagnosis, and type of tumor also influence the survival 
probability of patients. African-Americans are less likely to survive compared to other 
races, an effect mediated by tumor subtypes.16 
Even after many advancements in treatment and greater focus on screening, still 32% 
of 5% breast cancer patients are identified respectively in regional and distant stage of 
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tumors in the U.S., resulting in poor outcomes and shorter survival. In addition, breast 
cancer may be characterized by different molecular subtypes with varying severity2,17,18 
and survival rates, which contributes additional complexity.  
 
Literature Review 
Scientific literature was searched using databases from The National Library of 
Medicine Database (PubMed) and Google Scholar with query terms, “Breast cancer 
survival”, “Cancer survival” with “Disparity” “Health Insurance”, “Medicare”, 
“Medicaid”, “Managed care systems”, “Private health insurance”, “Sociodemographic 
status”, “Race”, “Income”.  
A study conducted in metropolitan Detroit explored the relationship between race, 
socioeconomic status, and breast cancer treatment and survival, and found race was not 
significantly associated with survival.  Low socioeconomic status, however, showed a clear 
association with late-stage breast cancer at diagnosis, type of treatment received and death. 
13,14 According to Surveillance, Epidemiology, and End Results (SEER) data in the 2000s, 
in the white population, breast cancer incidence was 127.4 per 100,000 annually, mortality 
was 12.3 per 100,000, and five-year survival was 90.4%.  In the African American 
population, however, incidence was 121.4 per 1000 population, mortality rate was 18.2 per 
100,000, and five- year survival was 78.6%, signifying huge disparities based on 
background characteristics.13 
Furthermore, many studies highlighted that breast cancer survival and cancer screening 
are lower when breast cancer patients had no health insurance12, 19, 20 drawing the attention 
of health care professionals towards this issue. Not only the lack of health insurance, but 
the type of health insurance a patient has been found to play a role. Privately insured 
women have, in general, a more favorable stage of disease at breast cancer diagnosis than 
do women who are insured through Medicare or Medicaid whereas uninsured women have 
the least favorable outcome compared to other groups.14 
A study conducted in California among the Latina ethnic group found lack of health 
insurance coverage to be strongest predictor of cancer screening underutilization.19 This 
gives rise to the number of women seeking health care at relatively advanced stage of the 
breast cancer further leading to risk of high mortality. Similarly, a study conducted in 
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Florida among female breast cancer patients diagnosed between 2007 and 2010 found that 
survival was worse for uninsured patients than privately insured patients with all stages.20  
In an older study conducted in 1993 by Ayanina et al., the adjusted risk of death in 
breast cancer patients was 49% higher for uninsured patients and 40% higher for Medicaid 
patients than for privately insured patients during the 54-89 months after diagnosis.21  
In another study conducted in Kentucky the three-year relative survival proportion of 
patients with breast cancer was 91% for the privately insured and 78% for uninsured 
patients. This clearly indicates favorable outcome for privately insured patients. This study 
also discovered the patients with Medicaid insurance had lower survival proportion 
compared to privately insured patients with other cancers such as prostate cancer, 
colorectal cancer and lung cancer too.22  
Access to health insurance influences the frequency and quality of health care, types of 
health care services and providers. Thus the insurance status of cancer patients may play 
important role in their survival. A New Zealand study that included 14,468 patients, there 
were differences in the characteristics of the patients themselves and the risk of mortality 
depending upon the type of health care centers they utilized for the treatment. Patients, 
treated in public centers, were older, belonged to minority ethnic groups, resided in poor 
neighborhoods and rural areas were less likely to be diagnosed with early staged cancer 
and to receive timely cancer treatments compared to women, who utilized private health 
centers. They also had a higher (14% more) risk of mortality from breast cancer, even after 
controlling for baseline demographic, disease and treatment factors.23 A retrospective 
cohort study conducted among patients registered in the Texas cancer registry found that 
those younger than 65 years without health insurance coverage had a significantly higher 
risk of mortality than those with private health insurance regardless of tumor stage, and 
treatment types.24 The early detection and the survival rate also varied depending on the 
health care delivery systems type for patients enrolled under the same insurance program. 
For this purpose, researchers studied breast care patients enrolled in Medicare, an 
entitlement health insurance for older age citizen in US. The study found differential 
outcomes depending on if patients were managed through Health Management 
Organizations (HMOs) or the Fee for Service (FFS) system. Medicare patients enrolled in 
HMOs were diagnosed at an earlier stage than FFS patients. HMO patients diagnosed with 
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breast and colorectal cancer had improved survival, and these differences remained even 
after controlling for potential confounders such as stage at diagnosis, age, race, 
socioeconomic status, and marital status. Patients enrolled in HMOs had 9% greater 
survival in hazards ratio if they had breast cancer, and 6% greater survival if they had 
colorectal cancer.25 Survival probability differs between blacks and whites even if they are 
diagnosed at similar stages of illness.26  
Similarly, the geographic residence of the patients also affects the survival of breast 
cancer patients. A study looking at the effect of distance from diagnostic hospital on 
screening found that 62% of total patients with distances greater than 20 km (n=347) had 
a late stage at diagnosis compared to 50% with distances less than 20 km. The risk of late 
stage at diagnosis significantly increased by 1.25-fold for each 30 Km increase in 
distance.27  
A study by Shi et al. found that compared to white patients, black patients had a 31% 
(1.31) increase, and other race had a 22% (0.78) decrease risk of death among breast cancer 
patients. Patients with higher comorbidity index ≥ 2 (2.27) and 1 (1.43) Charlson 
Comorbidity were more likely to die than those with no comorbid conditions.12 
Other studies have also reported that insurance types, race/ethnicity, comorbidity, 
geographic region or residence were associated with tumor stage at the time of diagnosis 
and increased risk of deaths in breast cancer patients.16, 26,28,29 A study by Warmer et al. 
found blacks had a 21% higher risk of breast cancer-specific death in multivariate adjusted 
models and the survival difference was prominent in estrogen receptor-positive tumors. 
Blacks were 76% and 56% more likely to die as a result of Luminal A-like and Luminal-B 
like tumors respectively, compared to their white counterparts.16 Survival was primarily 
different in those tumors for which survival could have been lengthened by hormonal 
treatment.  
Previous research has shown that survival of female breast cancer patients is affected by 
numerous factors including health insurance, race, comorbidity, hormonal receptor status, 
stage at the time of diagnosis, and geographical location. Patients are likely to have better 
survival if they have private insurance followed by Medicare.  The effect of insurance on 
cancer survival in Kentucky is understudied and this present study seeks to fill that gap by 
exploring the effect of health insurance for female breast cancer patients of Kentucky.  
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The primary objective of the study was to evaluate the effect of health insurance types on 
the survival of breast cancer patients, and type of treatment patients utilize.  The secondary 
objective was to assess other socio-demographic, biological factors that affect survival of 
the patients. 
 
Research Question. Do the types of health insurance affect survival of the breast cancer 
patients? 
 
METHODS  
This was a retrospective cohort study which included secondary analysis of existing data 
from the Kentucky Cancer Registry (KCR). 
 
Study population. The study included women aged 19 or older with a primary diagnosis 
of breast cancer registered in the KCR. There were 47,128 total patients diagnosed with 
primary breast cancer from 2000 to 2015. Patients with missing information on health 
insurance status and types or insurance other than Medicare and Medicaid were excluded 
from the study Patients, who were in TRICARE, military personnel or their dependents 
who are treated as a military facility, veterans who are treated in Veterans Affairs facilities, 
Indian/Public Health service patients who receives care at an Indian Health Service facility 
and costs are reimbursed by the Indian Health Service were also excluded from the study. 
Hence, there were 39, 271 patients had complete information on payer status.  
 
Data source and study population. This study included women aged 19 and older 
diagnosed with primary breast cancer and registered in the Kentucky Cancer Registry from 
2000 to 2015. Data was from Kentucky Cancer Registry (KCR). KCR is a statewide 
population-based registry that serves as the foundation for measuring the Kentucky cancer 
burden, comprehensive cancer control efforts, health disparities, progress in prevention, 
diagnosis, treatment and survivorship. Data are collected for the types of cancers, disease 
stage, types of first course treatment received by patients, and patient characteristics. 
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Study Variables  
Outcome variable 
The outcome variables for this study were five-year and ten-year survival. Length of 
survival was defined as time from the date of diagnosis to a 60 months and 120 months.  
 
Independent variable 
Primary independent variables.  Health Insurance status of the breast cancer patients was 
the primary independent variable. The health insurance status of the patients at the time of 
diagnosis was be categorized into three different levels: (1) Public Health Insurance e.g.,  
Medicaid and Medicare (2)  Private Health Insurance; and (3) No Health Insurance. 
 
Secondary independent variables. In addition to type of treatment, the analysis included 
socio-demographic factors as well as specifics about cancer type (e.g., biological and tumor 
factors). 
Type of treatment 
 
For this analysis, four categories were defined: (1) no intervention, (2) surgery at primary 
site only, (3) other combination of treatment except surgery and (4) surgery at primary 
site and at least other type of therapies.  
Socio-demographic factors 
- Appalachia: Kentucky can be divided into geographical regions of Appalachia and non-
Appalachia. Appalachian region is a cultural region of Appalachia that spreads along the 
spine of the Appalachian Mountains. The levels of Appalachia are residents of 
Appalachia=0, residents of non-Appalachia=1. 
- Race: Depending on the proportion of racial groups, the participants were categorized 
into one of three categories:  0= African American, 1= Other, 2=Caucasian. 
- Age of the patient at the time of diagnosis: Categorized into three groups (19-39, 40-64, 
equal to or over 65 years). 
- Marital status: Classified into three categories (1) single; (2) married and not living with 
partners, including widowed, separated, divorced; and (3) married. 
- Family history:  Categorized into two groups as family history having breast cancer and 
without family history of breast cancer.  
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- Tobacco use: Patients were categorized based on the history of tobacco use as tobacco 
user, non-user, or unknown.  
Biological and tumor factors 
- Surveillance, Epidemiology, and End Results (SEER) summary stage of breast cancer at 
diagnosis: SEER divides the breast cancer patients based on the extent of spread of 
cancer. It is defined as 1= In-situ and Localized, 2= Regional, 3= Distant. 
- Estrogen Receptor (ER) and Progesterone Receptor (PR) status: Estrogen receptor status 
was dichotomized into 1= ER positive (ER+) and 2= ER negative (ER-). Cases recorded 
as having a borderline ER will also be classified as ER receptor-positive. Progesterone 
receptor status was also dichotomized into PR positive (PR+) and PR negative (PR-). 
Cases recorded as having a borderline PR status will also be classified as PR receptor- 
- Menopausal status:  Menopausal status was dichotomized into premenopausal status, and 
postmenopausal status. 
-Tumor grade: Tumor grade was categorized into five categories as well differentiated, 
moderately differentiated, poorly differentiated, undifferentiated, non-high grade.  
 
Data analysis 
Data were analyzed using 9.4 version SAS software package. Kaplan-Meier curves and 
log-rank tests were used to assess the univariate association between breast cancer patient 
survival, and the types of health insurance. Impact of health insurance was further 
evaluated by controlling effects of socio-demographic variables, tumor and biological 
variables and health care related factors with multivariable Cox Proportional model.  We 
also performed sub-group analysis by SEER summary stage and age group to find the 
effect of health insurance controlling effect of all other variables. We included 
observations with complete information about all the covariates in multivariable Cox 
regression. Multivariable Cox proportional hazards models was then used to assess the 
association between breast cancer patient survival and types of health insurance adjusting 
for aforementioned other factors. The backward model selection was performed. 
Significance was set at p<0.05 (2-tailed). We also plotted map of counties of Kentucky 
corresponding to the number of deaths due to breast cancer during our study period. 
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Ethical Statement 
IRB approval with an exempt application was obtained from the University of Kentucky, 
Office of Research Integrity and we applied to KCR for release of data along with 
application and approval letter from IRB, Kentucky Cancer Registry released the dataset 
upon approval for release.  However, we couldn’t obtain personal health information such 
as geographical location of the patient’s residence and details about health care facilities 
and providers due to nature of ethical considerations we obtained and time constraints. 
KCR doesn’t collect information on education and income.  
 
RESULTS 
 
There were 47,128 total female patients diagnosed with primary breast cancer from 
2000 to 2015. However, there were only 39,271 observations were included in the study 
with complete information about the primary payer in file. Out of 39,271 patients, 11,663 
had event of death.  
The sample description is provided in Table 1. Comparatively higher proportion of the 
patients were covered under Medicare (47.71%) followed by private (40.84%) and 
Medicaid (11.45%) insurance scheme. A majority of the patients were Caucasian (92.13%) 
followed by African American (7.13%) and others constituted 0.74% of the total 
participants. About half (50.99%) of the patients belonged to 40-65 age category and 
44.86% of the patients aged equal to or over 65 years. About a quarter (24.96%) of the total 
patients belonged to Appalachian region. Majority of the participants (66.90%) were in 
post-menopausal phase whereas 13.52% of the participants didn’t have any information on 
menopausal status. Significant proportion of the patients (30.79%) had family history of 
breast cancer. However, 22.44% of the patients didn't have any information on family 
history. About half (53.14%) of the participants were married and 19.29% were widowed.  
A higher percentage of patients (71.94%) had surgery at primary site and at least 
another type of treatment such as chemotherapy, radiotherapy or other type of therapy. A 
majority of the patients (53.24%) had localized staging of breast cancer according to SEER 
summary stage followed by regional, in-situ and distant respectively. Similarly, majority 
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of patients were estrogen receptor positive (71.26%) and progesterone receptor positive 
(61.55%). Fewer than half (30.93%) of the breast cancer patients had poorly differentiated 
tumor.  
 
Table 1: Description of the study population from KCR, 2000 to 2015 
Characteristics Category Frequency Percent 
Primary Payer Medicaid 4497 11.45 
 Medicare 18737 47.71 
 Private 16037 40.84 
Race Caucasian 36182 92.35 
 African American 2800 7.15 
 Others 196 0.50 
Age(years) 19-39 1629 4.15 
 40-64 20024 50.99 
 ≥65  17618 44.86 
Appalachia Non-Appalachian 29469 75.04 
 Appalachian 9802 24.96 
Marital Status at 
Diagnosis 
Single  3602 9.17 
 Married  20869 53.14 
 Separated  298 0.76 
 Divorced  4508 11.48 
 Widowed  7575 19.29 
 Unmarried or domestic 
partner 
39 0.10 
 Unknown  2380 6.06 
Family History Yes  12090 30.79 
 No  18366 46.77 
 Unknown  8814 22.44 
Menopausal Status pre-menopausal  7692 19.59 
 post-menopausal  26271 66.90 
 Unknown  5308 13.52 
SEER Summary 
Stage 
In-situ  6225 16.01 
 Localized  20701 53.24 
 Regional  10001 25.72 
 Distant  1953 5.02 
ER Status Positive  27979 71.26 
 Negative  7275 18.53 
 Unknown  4012 10.22 
PR Status Positive  24170 61.55 
 Negative  10764 27.41 
 Unknown  4332 11.03 
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Tumor Grade Well differentiated 7353 18.72 
 Moderately differentiated 15003 38.20 
 Poorly differentiated 12145 30.93 
 Undifferentiated 892 2.27 
 Non-high grade 3878 9.87 
Tobacco Use Never user 19094 49.04 
 Cigarette smoker 13331 34.24 
 Cigar/pipe smoker 29 0.07 
 Snuff/chew/smokeless 
tobacco user 
47 0.12 
 Mixed use of more than one 
type of tobacco product 
21 0.05 
 Unknown/ not recorded 6416 16.48 
Treatment No intervention 948 2.41 
 Surgery at primary site only 8688 22.12 
 Surgery at Primary site and 
other therapy 
28253 71.94 
 Other combination of 
therapies other than surgery 
1382 3.52 
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We also mapped the fatality rate of counties to illustrate how deaths were distributed in 
Kentucky. Figure 1 shows the map of counties corresponding to hazard rate due to breast 
cancer per county during the period of 2000 to 2015. The hazard of death is most 
concentrated in counties in Appalachian region and western part of Kentucky. 
 
 
Figure 1: Case fatality rate for breast cancer by county among women, 2000 to 
2015.   
 
 
Univariate effect of health insurance policy on survival for breast cancer patients 
 
We included 39,271 patients for univariate survival analysis using log rank test and a 
Kaplan Meier survival curves were produced. Out of total 4497 Medicaid enrolled women, 
31.02% had event of death; out of 18,737 Medicare enrolled women, 43.81% had event of 
deaths and out of 16,037 women with private insurance, 12.84 % had event of deaths (Table 
2).  
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Table 2: Number of events per health insurance policy 
Insurance 
Scheme 
Total Death Censored Censored % Death % 
Medicaid 4497 1395 3102 68.98 31.02 
Medicare 18737 8209 10528 56.19 43.81 
Private 16037 2059 13978 87.16 12.84 
Missing and 
other 
7857 1895 5962 75.88 24.12 
 
We performed log-tank test to analyze the effect of health insurance on survival 
probability of women and found significant difference in survival of women in three 
different health insurance policies. Women in Medicare group had the least survival 
probability whereas the women in private insurance had higher survival throughout the 
follow up duration as shown in Figure 2.  
 
 
Figure 2: Kaplan Meier survival curve showing survival probability in three 
different insurance policy 
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There was a significant difference in survival for women between every one of 
insurance group with the other two groups of insurance schemes (Table 3).  
 
Table 3: Log-rank test for multiple comparisons of health insurance groups 
Adjustment for Multiple Comparisons for the 
Log rank Test 
 
Strata Comparison Chi-Square p-value 
payer payer Raw Tukey-
Kramer 
Medicaid Medicare 1570.1 <.0001 <.0001 
Medicaid Private 1918.6 <.0001 <.0001 
Medicare Private 3485.9 <.0001 <.0001 
 
The survival probability were 0.97, 0.76, and 0.71 for women with private, Medicaid 
and Medicare respectively, at 60 months whereas the survival probability was 0.82, 0.60 
and 0.48 for women with private, Medicaid and Medicare respectively, at 120 months.  
There were 21,473 total cases having complete information of the variables. Among 
them, 16,089 (74.93%) of the patients didn’t have event of deaths due to loss to follow up 
and the study time frame, and 5384 (25.07%) patients had event of death. There were 21 
parameters in the model and the number of events (5384) were enough for this 
multivariable cox regression.  
 
Multivariable effect of health insurance types on survival for breast cancer patients 
Table 4 displays the results of hazard ratio (HR) of death from a multivariable cox 
regression analysis. After adjusting for secondary factors, health insurance status had 
significant effect for overall survival of patients. Medicare and Medicaid payer status had 
significantly increased hazard of dying compared to private, with increase of 96% (HR 
=1.94 p-value<.0001), 89% (HR=1.88 p-value<.0001) respectively.  
There were two direct health care related factors including treatment patients utilized 
and payer or health insurance status of the patients. Both factors were significantly 
associated with survival of patient in the hazard model. For the purpose of regression 
analysis, treatment was categorized into four different levels including a group of no 
intervention, combination of therapies other than surgery at primary site, surgery at primary 
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site only and the most comprehensive treatment of surgery at primary site along with at 
least other treatment alternatives. Compared to women who received no intervention, 
women having surgery at primary site and at least one other therapy had 0.15 (HR=0.15, 
p-value<.0001) times less hazard of death. Similarly, patients who got surgery at primary 
site only had significantly less hazard of death (HR=0.24, p-value<.0001) and patients who 
received other combination of therapies but no surgery had 0.46 (0.46, p-value<.0001) 
times less hazard of death compared to women having no intervention at all.   
 Similarly, other socio-demographic factors such as age, marital status, tobacco use, 
family history of breast cancer were significantly associated with the hazard of death from 
breast cancer. However, the geographical location of patients as Appalachia and non-
Appalachia and the race of the patients didn’t have a significant relationship with the 
survival of the breast cancer patients when adjusted with other covariates. Women in the 
19-39 age group had a 33% (HR=0.67, p-value<.0001) decreased hazard of death 
compared to women equal to or over 65 years old. Similarly, women in the 40-64  age 
group had a 41% (HR=0.59, p-value<0.0001) less hazard of death compared to women in 
the 65 years and older age group.  
Patients with no history of tobacco use had a decreased hazard of hazard compared to 
tobacco users, with a significant decrease of 24% (HR=0.76, p-value<.0001). Women 
having no family history had a 15% (HR=1.15, p-value≤.0001) higher hazard of death 
compared to women having family history of breast cancer. Married women or those living 
with their partners had a 26% (HR =0.74, p-value<.0001) less hazard of death compared 
to single women whereas women who were widowed, divorced or separated had a 17% 
(HR=1.17, p-value=0.0045) higher hazard of death from breast cancer compared to single 
women. Similarly, women in post-menopausal phase had a 16% (HR=1.16, p-value= 
0.0041) higher hazard of death compared to pre-menopausal women even after adjusting 
with other covariates.  
The tumor and biological co-variates which included tumor grade, estrogen receptor 
status, progesterone receptor status, SEER summary stage were also significantly 
associated with survival of breast cancer patient in this cox proportional hazard model. 
Patients with moderately differentiated and poorly-differentiated tumor grade had 
statistically increased hazard of death with significant increase of 14% (HR=1.14, p-value 
  21 
=0.0024) and 39% (HR=1.39, p-value<0.0001) respectively. However, women with 
undifferentiated and non-high grade tumor didn’t have significant effect on hazard of death. 
Women with estrogen receptor negative breast cancer had a 14% (HR=1.14, p-
value=0.0032) higher hazard of death compared to women with estrogen receptor positive 
breast cancer. Likewise, progesterone receptor negative breast cancer had a 25% 
(HR=1.25, p-value<.0001) higher hazard of death compared to progesterone receptor 
positive breast cancer. SEER summary stage also had significant impact on survival for 
breast cancer patients controlling effect of other variables. Women with distant stage of 
cancer had a 245% (HR=3.45, p-value<.0001) higher hazard of death whereas women with 
in-situ and localized cancer had a 53% (HR=0.47, p-value <.0001) less hazard of death 
respectively compared to women with regional stage of breast cancer. 
Table 4: Multivariable Cox Proportional Regression: Hazard Ratio and 95% 
CI of Hazard ratio per covariate 
Group of 
Covariates 
Co-
variates 
and Levels 
Level of 
Covariates 
Hazard 
Ratio 
95% CI of 
Hazard ratio 
p-value 
Lower  Upper 
Health care 
access 
covariates 
Health 
Insurance 
Medicaid 1.89** 1.71 2.10 <.0001 
 Medicare 1.96** 1.75 2.18 <.0001 
 Private Ref.    
 Medicaid vs 
Medicare 
0.97 0.86 1.09  
Treatment Surgery at 
Primary site and 
other therapy  
0.15** 0.13 0.18 <.0001 
 Surgery at 
Primary site 
only  
0.24** 0.20 0.29 <.0001 
 Other 
combination of 
therapies other 
than surgery  
0.46** 0.38 0.56 <.0001 
 No intervention Ref.    
*Socio-
Demographic 
 
Age 19-39 0.67** 0.55 0.82 <.0001 
 40-64 0.59** 0.54 0.66 <.0001 
 ≥65 Ref.    
Appalachia Appalachia 1.02 0.96 1.09 0.5483 
Non-
Appalachia 
Non-Appalachia Ref    
Race African-
American 
1.71 0.91 3.20 0.0940 
 Caucasian 1.65 0.89 3.07 0.1143 
 Others Ref    
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Tobacco 
use 
Never user 0.76** 0.72 0.80 <.0001 
 Tobacco user Ref.    
Family 
history of 
breast 
cancer 
No family 
history 
1.15** 1.09 1.22 <.0001 
 Have family 
history 
Ref.    
Marital 
status 
Married 
 
0.74** 0.67 0.81 <.0001 
 Not with 
partners 
(widowed, 
divorced, 
separated) 
1.17** 1.06 1.29 0.0045 
 Single Ref.    
Tumor and 
Biological 
Characteristics 
Menopausal 
status 
Post-
menopausal 
status 
1.16** 1.05 1.28 0.0041 
 Pre-menopausal 
status 
Ref.    
Tumor 
grade 
Moderately 
differentiated 
1.14** 1.05 1.24 0.0024 
 Non-high grade 1.03 0.91 1.16 0.6112 
 Poorly-
differentiated 
1.39** 1.27 1.52 <.0001 
 Undifferentiated 0.94 0.75 1.18 0.6060 
 Well 
differentiated 
Ref.    
ER status Negative 1.14** 1.05 1.25 0.0032 
 Positive Ref.    
PR status Negative 1.25** 1.16 1.35 <.0001 
 Positive Ref.    
SEER 
summary 
stage 
Distant 3.45** 3.09 3.85 <.0001 
 In-situ & 
localized 
0.47** 0.44 0.50 <.0001 
 Regional Ref.    
* KCR doesn’t collect information on Education and Income of the patients. 
**significance at p-value <0.01 
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Effect of health insurance types on survival for patients with subgroup analysis by 
SEER summary stage  
We also performed sub-group analysis by SEER summary stage in multivariable Cox 
hazard model to find the effect of health insurance on survival for the patients in different 
groups of SEER summary stage (Table 5).  
Having private insurance is a highly protective factor for patients in all stages for 
survival of the patients. Medicaid and Medicare patients had 2.13 (HR=2.13, p-
value<.0001) and 2.12 (HR=2.12, p-value<.0001) times higher hazard of death compared 
to privately insured patients for in-situ and localized groups. Medicaid and Medicare 
patients had 1.75 (HR=1.75, p-value<.0001) and 1.92 (HR=1.92, p-value<.0001) times 
higher hazard of death compared to privately insured patients for regional stage group and 
Medicaid patients had 1.41(HR=1.41, p-value=0.0020) times higher hazard of death 
compared to privately insured patients whereas Medicare patients and the privately insured 
patients had no difference in hazard of death for distant stage group.  
Having some treatment decreased hazard of death for all stages of cancer. Surgery at 
primary site and at least one other therapy had lowest hazard of death compared to surgery 
at primary site only group for patients in all summary stage. Patients, who received surgery 
at primary site and at least one other therapy had an 88%, 87% and 81% lower hazard of 
death compared to patients who received no treatment respectively for in-situ, regional and 
distant stage.  
When survival rate was analyzed by stratifying the patients based on summary stage of 
cancer, age had significant effect on survival for patients with in-situ and localized and 
regional stage whereas the effect of age was not significant for patients with distant stage. 
Patients with in-situ and localized stage in age category of 19-39 had a 59% lower hazard 
of death compared to those in the 65 years or older age group. 
Appalachian patients with in-situ and localized breast cancer stage had a 10% 
(HR=1.10, CI=1.21-1.01) higher hazard of dying compared to non-Appalachian patients 
whereas the Appalachia status had minimal effect on patients with regional and distant 
stage. Marital status had significant association with survival of patients in all the stages. 
Married patients had consistently lower hazard of death compared to single and the 
participants not living with partners had a comparatively higher hazard of dying. 
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Participants, who were not living with partners, with localized stage had a 27% (HR=1.27, 
CI=1.09, 1.48) higher hazard of death compared to single participants.  
Never using tobacco was a positive factor for survival for patients with localized and 
regional stage whereas tobacco use was not significant for survival of patient with distant 
stage. Patient who never used tobacco were 29% and 26% less likely to die compared to 
patient who had history of tobacco use for localized and regional stage group respectively. 
Similarly, having family history of breast cancer had a protective effect on survival for 
patients diagnosed in localized and regional stage. However, family history had no 
significant effect for patients with distant stage. Patients with localized breast cancer in 
post-menopausal phase had a 33% greater hazard of death compared to women in pre-
menopausal phase.  
Compared to well differentiated tumor grade, patients in distant stages with moderately 
differentiated tumor had a significantly (82%) higher hazard of death. Similarly, patients 
with non-high grade in regional and distant stage had a 31% and 68% higher hazard of 
death.  Patients with poorly-differentiated tumor in localized, regional and distant stages 
had a 1.28, 1.37, and 2.23 times higher hazard of death, respectively. Remarkably, patients 
with localized cancer with undifferentiated tumor grade had a 24% lower hazard of death 
compared to patients with well differentiated tumor grade. Negative estrogen receptor 
status had increased hazard of dying in patients with regional (17%) and distant (33%) 
stages whereas negative progesterone receptor status had increased hazard of death in 
patients with localized (21%), regional (30%) and distant (31%) stages.   
Estrogen receptor status and race had no significant effect on survival for women with 
in-situ and localized summary stage patients. Appalachia, menopausal status and race had 
no significant effect on survival for patients with regional summary stage. Race, 
menopausal status, tobacco status, family history, Appalachia, and age had no significant 
effect on survival for women with distant summary stage.  
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Table 5: Effect of covariates on survival for the patients by SEER summary stage with 
multivariable Cox proportional hazard model 
Covariates In-situ and Localized Regional  Distant 
 Hazard 
ratio 
95% CI p-value Hazard 
ratio 
95% CI p-value Hazard 
ratio 
95% CI p-value 
Health Insurance          
Medicaid 2.13** 1.78,2.54 <.0001 1.75** 1.50,2.03 <.0001 1.41** 1.13,1.76 0.0020 
Medicare 2.21** 1.87,2.61 <.0001 1.92** 1.61,2.29 <.0001 1.26 0.95,1.67 0.1078 
Private Ref.   Ref.   Ref.   
Treatment     
Surgery at primary site 
and other therapy  
0.12** 0.09,1.17 <.0001 0.13** 0.08, 0.20 <.0001 0.19** 0.14, 0.25 0.0001 
Surgery at Primary site 
only  
0.20** 0.15,0.27 <.0001 0.21** 0.13, 0.32 <.0001 0.45** 0.30, 0.67 <.0001 
Other combination of 
therapies other than 
surgery  
1.03 0.69,151 0.8947 0.39** 0.24, 0.63 <.0001 0.44** 0.34, 0.57 <.0001 
No intervention Ref.   Ref.   Ref.   
Age          
19-39 0.41** 0.28, 0.62 <.0001 0.84 0.64, 1.11 0.2225 0.68 0.43, 1.07 0.0977 
40-64 0.49** 0.47, 0.57 <.0001 0.70** 0.59, 0.82 <.0001 0.77 0.59,1.00 0.0524 
≥65 Ref.   Ref.   Ref.   
Appalachia          
Appalachia 1.10 0.99, 1.20 0.0543 0.99 0.89, 1.10 0.8427 0.95 0.80,1.12 0.5138 
Non-Appalachia Ref.   Ref.   Ref.   
Race          
African American 1.48 0.55, 3.99 0.4371 2.50 0.80, 7.86 0.1159 1.00 0.31, 3.20 0.9998 
Caucasian 1.65 0.62, 4.41 0.3156 2.21 0.71, 6.86 0.1721 0.93 0.30, 2.95 0.9075 
Other Ref   Ref.   Ref.   
Tobacco use    
Never user 0.71** 0.65, 0.76 <.0001 0.74** 0.67, 0.81 <.0001 1.03 0.89, 1.19 0.7111 
Tobacco user  Ref.   Ref.   Ref.   
Family History    
No family history 1.14** 1.05, 1.24 0.0012 1.21** 1.10, 1.33 <.0001 1.06 0.91, 1.24 0.4487 
Have family history  Ref.   Ref.   Ref.   
Marital Status          
Married 0.70** 0.60, 0.82 <.0001 0.84* 0.72, 0.99 0.0383 0.77* 0.62, 0.96 0.0203 
Not with 
partners(widowed, 
divorced, separated) 
1.26** 1.08, 1.47 0.0034 1.17 0.99, 1.37 0.0568 1.03 0.82, 1.30 0.7831 
Single Ref.   Ref.   Ref.   
Menopausal Status  
Post-menopausal status 1.33** 1.12, 1.58 0.0012 1.10 0.95, 1.28 0.1985 1.02 0.81,1.30 0.8349 
Pre-menopausal status  Ref.   Ref.   Ref.   
Tumor Grade          
Moderately differentiated 1.07 0.97, 1.18 0.1811 1.10 0.95, 1.28 0.1985 1.82** 1.28, 2.58 0.0009 
Non-high grade 0.91 0.76, 1.08 0.2698 1.31** 1.10, 1.56 0.0029 1.68** 1.16, 2.43 0.0058 
Poorly-differentiated 1.28** 1.14, 1.44 <.0001 1.37* 1.07, 1.76 0.0121 2.23** 1.56, 3.18 <.0001 
Undifferentiated 0.74* 0.55, 0.99 0.0438 1.67** 1.40, 2.00 <.0001 1.90 0.99, 3.67 0.0543 
Well differentiated  Ref.   Ref.   Ref.   
ER status  
Negative 1.04 0.91, 1.19 0.5746 1.17* 1.02, 1.34 0.0289 1.33** 1.06, 1.66 0.0124 
Positive  Ref.   Ref.   Ref.   
PR status  
Negative 1.21** 1.08, 1.35 0.0010 1.30** 1.15, 1.48 <.0001 1.31** 1.07, 1.61 0.0086 
Positive  Ref.   Ref.   Ref.   
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*Significant at p-value<.05    **Significant at p-value<.01 
 
Effect of health insurance types on survival for patients with subgroup analysis by 
age group  
We further analyzed the effect of insurance types on hazard of death by age groups 
(Table 6). Of the total 1629 patients in the youngest (19-39 years) age group, 948 patients 
were included in the regression analysis, 182 (19.19%) had event of death. Of the total 
17,618 patients in the oldest age group ( ≥65 years), 9531 patients were included in the 
regression analysis and 3527 (37%) patients had event of death. In the 40-64 age group, 
(total of 20,024 patients), 10,994 were included in the regression analysis, 1675 (15.24%) 
had event of death.  
In this regression model, the hazard of death was significantly higher for patients with 
Medicaid and Medicare compared to women with private insurance in the (18-39)-year age 
group and 40-65 age group. However, for patients over or equal to 65-year age group, there 
was no significant difference in hazard of death between patients enrolled in private and in 
Medicaid insurance.  
In the 19-39 age group, the hazard of death is 84% and 116% higher for patients 
enrolled in Medicaid, Medicare respectively compared to patients with private insurance. 
Appalachia, race, family history, tobacco status, marital status, menopausal status, estrogen 
receptor status, progesterone receptor status, and weren’t associated with the survival of 
women in the 19-39 age group.   
The hazard of death was significantly higher for patients with Medicaid and Medicare 
insurance compared to women with private insurance in 40-64 age group with increased 
hazard of 91% and 127% respectively. Appalachia and race weren’t associated with 
survival of patients in the 40-64 age group. 
Patients enrolled in Medicare had significantly (45%) higher hazard of death compared 
to women with private insurance in the 65 years or older age group. Appalachia, 
menopausal status, race, and estrogen receptor status had no significant impact on survival 
for patients 65 years or older (Table 6). 
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Table 6: Effect of Covariates on Survival for breast cancer patients by Age groups with 
Multivariable Cox Proportional Hazard Model 
Covariates 
 
19-39 years 40-64 years ≥65 years 
Hazard 
ratio 
CI p-value Hazard 
Ratio 
CI p-value Hazard 
ratio 
CI p-value 
Health Insurance          
Medicaid 1.84** 1.31, 2.60 0.0005 1.91** 1.69, 2.15 <.0001 1.30 0.89,1.89 0.1820 
Medicare 2.16* 1.05, 4.44 0.0352 2.27** 1.97, 2.60 <.0001 1.45** 1.20, 1.75 0.0001 
Private Ref.   Ref.   Ref.   
Treatment   
Surgery at Primary site 
and other therapy  
27343.95 0,1.25E298 0.9764 0.12** 0.08, 0.18 <.0001 0.14** 0.11,0.17 <.0001 
Surgery at Primary site 
only  
21140.69 0, 9.66E297 0.9770 
 
0.15** 0.10, 0.22 <.0001 0.23** 0.19, 0.29 <.0001 
Other combination of 
therapies other than 
surgery  
151479.6 0, 6.92E298 0.9724 
 
0.30** 0.20, 0.46 <.0001 0.45** 0.36, 0.56 <.0001 
No intervention Ref.   Ref.   Ref.   
Appalachia          
Appalachia 1.32 0.92, 1.89 0.1274 1.04 0.93, 1.17 0.4624 0.99 0.92, 1.08 0.8787 
Non-Appalachia Ref.   Ref.   Ref.   
Race          
African American 1.66 0.39, 7.07 0.4954 2.06 0.76, 5.56 0.1550 1.69 0.63, 4.55 0.2998 
Caucasian 1.02 0.25, 4.23 0.9738 2.10 0.78, 5.61 0.1398 1.66 0.62, 4.44 0.3115 
Other Ref.   Ref.   Ref.   
Tobacco Use  
Never user 0.72* 0.52, 0.99 0.0448 0.70** 0.64, 0.78 <.0001 0.78** 0.73, 0.84 <.0001 
Tobacco user  Ref.   Ref.   Ref.   
Family History  
No family history 0.88 0.65, 1.19 0.4149 1.19** 1.07, 1.31 0.0008 1.16** 1.08, 1.24 <.0001 
Have family history  Ref.   Ref.   Ref.   
Marital Status          
Married 0.84 0.58, 1.22 0.3578 0.86 0.74, 1.01 0.0588 0.67** 0.58, 0.77 <.0001 
Not with 
partners(widowed, 
divorced, separated) 
0.99 0.62, 1.59 0.9870 1.15 0.98, 1.34 0.0954 1.15 0.99, 1.31 0.0515 
Single Ref.   Ref.   Ref.   
Menopausal Status  
Post-menopausal status 1.32 0.76, 2.28 0.3243 1.15** 1.03,1.27 0.0109 0.91 0.49, 1.69 0.7550 
Pre-menopausal status  Ref   Ref   Ref   
Tumor Grade          
Moderately differentiated 1.66 0.65, 4.25 0.2914 1.29** 1.08, 1.54 0.0039 1.11* 1.01,1.22 0.0280 
Non-high grade 2.12 0.69, 6.52 0.1881 1.13 0.89, 1.43 0.3095 1.02 0.88,1.17 0.8133 
Poorly-differentiated 2.44 0.96, 6.20 0.0615 1.58** 1.32, 1.89 <.0001 1.36** 1.22, 1.51 <.0001 
Undifferentiated 4.16* 1.16,14.86 0.0284 1.10 0.73, 1.66 0.6495 0.87 0.65,1.16 0.3445 
Well differentiated  Ref.   Ref.   Ref.   
ER status  
Negative 1.10 0.68, 1.77 0.7062 1.25** 1.07, 1.45 0.0045 1.08 0.96,1.20 0.1999 
Positive  Ref.   Ref.   Ref.   
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PR status  
Negative 1.18 0.73, 1.90 0.4958 1.38** 1.20, 1.59 <.0001 1.20** 1.09, 1.32 0.0001 
Positive  Ref.   Ref.   Ref.   
SEER stage  
Distant 2.06* 1.09, 3.90 0.0260 4.27** 3.61, 5.05 <.0001 3.02** 2.60,3.51 <.0001 
Localized 0.23** 0.15, 0.35 <.0001 0.35** 0.31, 0.39 <.0001 0.56** 0.52,0.60 <.0001 
Regional Ref.   Ref.   Ref.   
*Significant at p-value<0.05    **Significant at p-value<0.01  
 
DISCUSSION  
The purpose of this study was to evaluate the effect of types of health insurance and 
other socio-demographic factors on survival for women with breast cancer.  We included 
women with breast cancer to understand their survival based on their health insurance types 
and other covariates. We found that the survival is highest among patients with private 
insurance while the patients with Medicaid and Medicare had comparatively lower survival 
probability post-diagnosis. Effect of health insurance on hazard of death was still present 
even after controlling other socio-demographic factors, tumor and biological 
characteristics and treatment factors in the regression model. The hazard ratio was higher 
for Medicare patients (94% vs 88%) than Medicaid patients compared to patients with 
private health insurance. Previous studies have shown that uninsured and Medicaid 
enrolled patients are at increased hazard of death compared to privately insured breast 
cancer patients. A study by Gorey et. al. (2011) using a California population and another 
study using data from Texas Cancer Registry by Zhang et.al. (2015) concluded that 
privately insured women were at an advantage on survival compared to the uninsured or 
those insured by Medicaid.11, 24 Other studies have  focused on the differential effect on 
survival due to private and Medicaid insurance. However, Medicare patients are also 
significantly disadvantaged for survival compared to patients with private health insurance 
as depicted in this study.  
When multivariable Cox regression was performed to evaluate effect of health 
insurance controlling effects of other covariates by age group, the hazard was insignificant 
between patients with Medicaid and private insurance in older than 65-year age group. 
However, the hazard of death was significantly higher (45%) for patients with Medicare 
compared to patients with private insurance. Even though some other socio-demographic 
factors, tumor and biological factors lost their significance in the multivariable model, 
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health insurance and treatment type remained consistently significant in the model in all 
age groups. These findings highlight the importance of these health care factors in affecting 
survival of the breast cancer patients. 
A study by Shi et al (2013) found the survival outcome was different for patients 
enrolled in Medicaid and private health insurance even when patients got the same type of 
treatment administered by the clinicians in a public hospital.30 This differential outcome 
could be attributed to the fact that patients without private health insurance are diagnosed 
in the later stage of disease. The relationship of personal characteristics of the patient and 
the enrollment in the health insurance policy should also be taken into consideration.  
Some studies also implied differential quality of treatment rendered to patients 
depending upon their insurance coverage. A study done by Parikh-Patel et al. found that 
breast cancer patients in all other insurance groups including Medicare, Medicaid, 
uninsured group had significant lower odds (16-25%) of receiving radiation after breast 
conserving surgery (BCS) compared with the privately insured group.15 Similarly, for 
patients with four or more positive lymph nodes, uninsured and dual eligible patients had 
significantly lower odds of receiving radiation therapy after mastectomy.15 This finding 
was further supported by other studies conducted to assess impact of insurance types on 
the treatment pattern among breast cancer patients.30-34 Another study conducted in Florida 
by Voti et al. found that women with Medicaid at the time of diagnosis were 29% less 
likely to receive recommended treatment for breast cancer compared to patients with 
private insurance.35 Those finding suggest role of insurance in determining quality of health 
care they received and these findings should be taken into account while deciphering the 
mechanism by which health insurance affect the survival of the patients.  
Even within insurance types, differences in outcomes have been seen in patients in 
capitated and fee-for-service systems. A study by Kirsner et al., found that 13.1% of HMO 
patients were diagnosed in an in-situ stage compared with 10.8% of FFS patients for breast 
cancer.25 Similarly, Medicare patients enrolled in HMO healthcare delivery systems had 
greater survival when diagnosed with breast cancer, either as a first cancer diagnosis or 
subsequent cancer diagnosis compared with patients enrolled in FFS systems.29 The 
differences remained even after controlling for potential confounders. 
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One study hypothesized Medicaid patients would have a higher likelihood of late-stage 
disease at diagnosis and a lower likelihood of receiving radiation therapy compared to 
women not insured by Medicaid.  The difference being due to circumstances beyond the 
control of insurance status as such patients insured by Medicaid may have comorbid 
conditions that interfere with cancer screening and treatment and physicians may be 
reluctant to recommend routine screening or cancer treatment for low-income women, even 
those who are insured.14 
The effect of geographical distribution of the patients did not have any significant effect 
on survival of the patients though Appalachian patients had significantly higher hazard 
ratio compared to non-Appalachian patients in univariate Cox regression. Being married 
or living with partners were found to be a protective factor for survival of breast cancer 
patients. This finding could be related to the fact that having partner shortens the delay in 
seeking health care as was found in a population-based study done using register-sampled 
cancer patients in the Aarhus County, Denmark implying partner support to be significantly 
associated with shorter patient delay in health seeking among cancer patients.36 Partner 
support explains one way of advantage being in relationship at the time of diagnosis and 
subsequent care of breast cancer patients.     
 
Conclusion and Limitation 
 This study is based on secondary data analysis of breast cancer patients to determine the 
impact of health insurance on survival of breast cancer patients. This research project also 
depends on the only available structured information that limits potential of the researcher 
and the project to explore in depth mechanism by which health insurance affects survival. 
Original research with primary data could answer several questions about the quality and 
accessibility of health care services by the breast cancer patients. Health insurance ensures 
the access of health care when needed. Hence, including components of health care access 
such as appointments to care providers, type of health care providers, and treatment as 
intermediary model could be more useful to understand the pathways of disparities in 
survival probability due to health insurance. Lack of information about education and 
income might also affect the overall impact of health insurance on survival as their effect 
are not controlled in the regression model. 
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This issue has attained considerable attention from the government and other medical 
professionals and allied health care organizations. In the meantime, assessing the effect of 
health insurance on breast cancer patients underlines its importance in improving survival, 
and helps demonstrate the disparities in survival rates of breast cancer patients, as well as 
provides evidence regarding the discrepancy of health insurance types and their effects. 
Given the high burden and mortality of breast cancer among US women, this should be 
high priority among policymakers and health care professionals to ensure the availability 
and affordability of health care when needed to decrease the mortality and to increase the 
quality of life among survivors.  
This study shows a higher hazard of death in patients with Medicaid and Medicare 
compared to privately insured patients requiring an action to understand thoroughly how 
they are varied. This study also validates health insurance as an imperative modifiable 
factor of survival of breast cancer patients. Health insurance has been highly debated policy 
issues of US health care system and with expansion of Medicaid, it is pushed as right of 
every individual. However, our research supports that having health insurance is not 
sufficient enough, policy makers should be aware about how quality of health care and 
health outcome are affected by health insurance policies. It is highly recommended to 
ensure that those insurance policies provide at least the same basic level of coverage that 
brings equal health outcome for the disease.  
 
Recommendations 
 A detailed study to find out the financing detail in each insurance policy for treatment of 
breast cancer is recommended to understand any factors motivating care provider’s 
behavior. Further study detailing physician perspectives on how they recommend treatment 
and their perception about consideration of insurance while recommending treatment and 
patients perspectives on how they are recommended treatment based on insurance could 
help in understanding impact of health insurance in real life scenario. Hence, large scale 
original research projects could be performed to extract views and perceptions of those 
patients covered with different insurance types. Policy analysis of health insurance 
organizations regarding coverage of breast cancer patients can be carried out to understand 
policies of health insurance companies. 
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In conclusion, the findings from this study can help to inform public health 
professionals and policy makers about impact of health insurance on survival of female 
breast cancer patients and help to design policies that reduce disparity in health outcome 
depending on types of health insurance. Improving provision of health care services under 
Medicare and Medicaid may improve breast cancer outcomes. 
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